Shkreli's company acquired the rights to Daraprim—a 62-year-old treatment for newborns and HIV patients—and promptly raised its price from $13.50 to $750.
The show reaches roughly 11 million listeners each episode and has “tremendous influence" on those vulnerable to its “predatory medical misinformation," docs wrote.